Navigation Links
Ambit Biosciences Announces Third Quarter 2013 Operating Results
Date:11/7/2013

$3.1 million and $1.2 million for the quarters ended September 30, 2013 and 2012, respectively.  The increase of $1.8 million was primarily due to increased costs related to patent prosecution, personnel-related expenses, stock-based compensation expense and consulting for market research, organizational development and planning related to the return of full rights for quizartinib.

Other expenses (net) were $8.7 million and $2.0 million for the three months ended September 30, 2013 and 2012, respectively.  The increase of $6.7 million was primarily due to the change in fair value of the Company's stock warrant liabilities, which is driven by the change in fair value of the underlying preferred or common securities.

Year-To-Date Results
Revenues were $25.8 million and $14.7 million for the nine months ended September 30, 2013 and 2012, respectively.  The increase of $11.1 million was primarily due to acceleration in the recognition of license fee revenue related to the Company's collaboration with Astellas Pharma.  In March 2013, the Company received a notice of termination of the agreement from Astellas, which termination was effective September 2013. 

Research and development expenses were $20.2 million and $30.1 million for the nine months ended September 30, 2013 and 2012, respectively.  The decrease of $10.0 million was primarily due to lower quizartinib research and development expenses.  This resulted from a reduction in the number of patients being treated and followed in our Phase 2 clinical trial, for which enrollment of patients was completed in late 2011. 

General and administrative expenses were $7.0 million and $4.5 million for the nine months ended September 30, 2013 and 2012, respectively.  The increase of $2.5 million was primarily due to increased costs related to patent prosecution, stock-based compensation expense, personnel-related expenses and consulting for market res
'/>"/>

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Ambit Announces Participation At 12th Annual BIO Investor Forum
2. Ambit Announces Participation At The BioCentury NewsMakers in the Biotech Industry Conference
3. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
4. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
5. APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market Research Report at ReportsnReports.com
6. Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting
7. Ambit Biosciences to Present at Two Upcoming Investor Conferences
8. Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
9. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
10. Pressure BioSciences, Inc. Reports Third Quarter 2013 Financial Results and Provides Business Update
11. Juneau Biosciences Names Dr. Dinesh Patel to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 DTS Language Services, Inc . ... Portal for Life Science organizations who need document translations. ... matter of their documents in advance with a selection of ... of translations, often a critical factor in clinical and scientific ...
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: ... 1360 Almshouse Road, Warrington, Pa. , Details: The ... to finding a cure for hepatitis B and improving the ... annual Crystal Ball on Friday, April 11 at Warrington Country ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 EquitiesIQ, a ... Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical company ... the wound care market. , Free report download: ... with a seasoned management team and Board, which launched ...
(Date:1/14/2014)... , Jan. 14, 2014  RXi Pharmaceuticals Corporation (OTCQX: ... and commercializing innovative therapies addressing major unmet medical ... received the Notice of Allowance from the United ... self-delivering RNAi compounds (sd-rxRNA®), for the treatment of ...
Breaking Biology Technology:DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... LUMBY, BC, Sept. 1 /PRNewswire-FirstCall/ - avVaa World Health ... company, manufacturer and distributor of nationally branded therapeutic, natural ... successfully completed its first week of DRTV 120/60 second ... President and COO of avVaa World Health Care Products ...
... Delaware, September 1 According to a new,market research ... http://www.marketsandmarkets.com ), the,global autoimmune treatment market is expected ... CAGR of 12.7% from 2009 to 2014. The North,American ... the total revenues. , Browse ...
... ... + Phillips, Media Investment Bankers, has announced that James R. Brennan, ... IncumediX and COO/CSO at MediServe Information Systems, Jim currently runs a ... acquisitions, technology license and partnership deals, notably the sale of VanSlyck ...
Cached Biology Technology:avVaa World Health Care Products, Inc. Announces the completion of its first week of DRTV 120/60 second test commercials for Neuroskin(R) Psoriasis Relief 2MarketsandMarkets: Global Autoimmune Treatment Market Worth US$68.81 Billion by 2014 2MarketsandMarkets: Global Autoimmune Treatment Market Worth US$68.81 Billion by 2014 3MarketsandMarkets: Global Autoimmune Treatment Market Worth US$68.81 Billion by 2014 4DeSilva + Phillips, Mediabankers, names Jim Brennan to Head Healthcare IT M&A Practice 2DeSilva + Phillips, Mediabankers, names Jim Brennan to Head Healthcare IT M&A Practice 3
(Date:4/22/2014)... of breeding bird surveys sent in by citizen scientists ... years, wildlife researchers report that most of the 40 ... higher elevation in response to climate change, but did ... previous studies of potential climate change impacts on wildlife ... have likely underestimated the effects of environmental warming, say ...
(Date:4/22/2014)... is available in French . ... month, sequencing of the complete genome and subsequent phylogenetic ... a clade (variant) that is distinct from strains previously ... Gabon. Epidemiological investigations also linked the laboratory confirmed cases ... outbreak. , Ebola virus is a lethal, highly contagious ...
(Date:4/22/2014)... demonstrate how communities can protect themselves from worsening ... in New England and the Midwest providing practical ... "Our goal is to help communities begin the ... Stack, of Syntectic International, Portland, OR. "It,s important ... move beyond feeling paralyzed from the lack of ...
Breaking Biology News(10 mins):Wildlife response to climate change is likely underestimated, experts warn 2Inserm and the Institut Pasteur identify a new variant of Ebola virus in Guinea 2Minnesota projects offer hope and practical help to communities facing more extreme storms 2
... of the journal Cell Metabolism, published by Cell Press, ... glands of mammals meet the incredible metabolic demands of ... undoubtedly affect breast cancer, the findings may have therapeutic ... one of three “isoforms?of the gene known as Akt ...
... of biologists at New York University's Center for Comparative Functional ... The gene plays a part in ensuring that chromosomes are ... nuclear envelope function. The findings appear in the journal Current ... is using functional genomic tools to study the nematode worm ...
... war against flu, researchers at the University of Wisconsin-Madison ... confers broad protection against influenza viruses, including deadly avian ... (Oct. 4, 2006) in the Journal of Virology, describes ... molecule -- that effectively blocks the influenza virus from ...
Cached Biology News:How mammals fuel milk production may have implications for cancer 2How mammals fuel milk production may have implications for cancer 3NYU biologists identify gene that coordinates two cellular processes 2New drug blocks influenza, including bird flu virus 2New drug blocks influenza, including bird flu virus 3
Comp Dim: chamber diam. depth 20 2.8 mm chamber maximum volume 720 μL...
...
... A direct, simple approach ... the well surface of an ... anhydride maintains its integrity and ... under dry, room temperature conditions ...
... reagent; Ideal for clarifying many items ... nucleic acids, & proteoglycans; Contains no ... downstream processing; Utilizes a reagent that ... as a suspension in saline; Simple ...
Biology Products: